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Perspective
The Association between CRP and 
Diabetes
In this issue of PLoS Medicine, Eric 
Brunner and colleagues address 
the causal nature of the association 
between C-reactive protein (CRP), 
the classical acute phase reactant, and 
the presence of insulin resistance or 
diabetes [1], using a genetic approach 
known as “Mendelian randomisation.” 
Previous studies, including a 
literature-based meta-analysis of 
ten studies involving 2,675 cases of 
diabetes, have shown a significant 
association between the risk of diabetes 
and higher plasma levels of CRP 
[2]. However, it remains uncertain 
whether CRP is causally involved in the 
pathogenesis of diabetes. An alternative 
possibility to explain the association 
is that CRP is a confounder, since 
CRP is strongly associated with known 
causal risk factors for diabetes, such 
as obesity. A third possibility is reverse 
causality (i.e., diabetes causes a raised 
CRP), since the pathological processes 
leading to insulin resistance are known 
to operate from an early stage in life 
and could therefore be well established 
at the time of enrolment in prospective 
studies.
Mendelian Randomisation
In the Mendelian randomisation 
approach, investigators first identify 
genetic polymorphisms that affect 
levels of the risk factor whose causal 
significance is queried (in this 
case CRP). They then quantify the 
relationships between polymorphisms 
and risk factor, risk factor and disease, 
and polymorphisms and disease. If 
the hypothesised risk factor causes 
disease, it is anticipated that the 
association between the polymorphisms 
and disease risk will be at least 
commensurate with what would be 
“expected,” given the association 
between the polymorphisms and the 
risk factor, and the association between 
the risk factor and disease. 
Genotypes are randomly allocated 
at conception; therefore, if their effect 
is specific to the risk factor of interest, 
confounding ought not to influence 
any association between genotypes 
and disease. Since “randomisation” 
to a particular genotype takes place 
well before the onset of the disease 
of interest, reverse causality similarly 
should not explain any association 
observed. Mendelian randomisation 
therefore provides a potential method 
to assess the causality of associations 
described in epidemiological studies 
where suitably specific drugs to 
undertake randomised controlled trials 
are not yet available [3,4]. 
The New Study
Brunner and colleagues genotyped 
three single nucleotide polymorphisms 
(SNPs) in the CRP gene that together 
“tag” the common genetic variation 
present at the locus. They measured 
serum CRP in 5,274 men and women 
enrolled in the Whitehall II prospective 
study, and measured the incidence 
of diabetes, insulin resistance (using 
HOMA-IR, the homeostasis model 
assessment of insulin resistance), and 
haemoglobin A1c (HbA1c) thirteen 
years later. Serum CRP at mean age 49 
years was significantly associated with 
incident type II diabetes (270 cases) 
during thirteen years of follow-up. 
Serum CRP was also associated with 
HOMA-IR and HbA1c. The strength 
of the associations with diabetes or 
with HOMA-IR and HbA1c diminished 
substantially upon adjustment for 
potential confounders. 
As in previous studies, the authors 
found evidence of a significant 
association between CRP haplotypes 
(combinations of alleles along 
chromosomes) and serum CRP. There 
was, however, no association between 
the CRP haplotypes associated with 
higher serum CRP and either HOMA-
IR or HbA1c levels among 4,357 and 
5,266 individuals, respectively. The 
authors conducted an “instrumental 
variable” analysis using the CRP
haplotypes, which is equivalent to the 
More Evidence Against a Causal Association 
between C-Reactive Protein and Diabetes
Bernard Keavney
Funding: BK holds a British Heart Foundation chair. 
He received no specific funding for this article. 
Competing Interests: The author has declared that 
no competing interests exist.
Citation: Keavney B (2008) More evidence against a 
causal association between C-reactive protein and 
diabetes. PLoS Med 5(8): e174. doi:10.1371/journal.
pmed.0050174
Copyright: © 2008 Bernard Keavney. This is an 
open-access article distributed under the terms 
of the Creative Commons Attribution License, 
which permits unrestricted use, distribution, and 
reproduction in any medium, provided the original 
author and source are credited.
Abbreviations: CHD, coronary heart disease; CRP, 
C-reactive protein; Hb, haemoglobin; HOMA-IR, 
homeostasis model assessment of insulin resistance; 
LDL, low-density lipoprotein; LFIP, low-frequency, 
intermediate-penetrance; SNP, single nucleotide 
polymorphism; WTCCC, Wellcome Trust Case-Control 
Consortium
Bernard Keavney is British Heart Foundation 
Professor of Cardiology in the  Department of 
Cardiology and Institute of Human Genetics, 
University of Newcastle, Newcastle, United Kingdom. 
E-mail: b.d.keavney@ncl.ac.uk
The Perspective section is for experts to discuss the 
clinical practice or public health implications of a 
published article that is freely available online.
Linked Research Article
This Perspective discusses the 
following new study published in PLoS
Medicine:
Brunner EJ, Kivimäki M, Witte DR, 
Lawlor DA, Davey Smith G, et al. (2008) 
Inflammation, insulin resistance, and 
diabetes—Mendelian randomization 
using CRP haplotypes points upstream. 
PLoS Med 5(8): e155. doi:10.1371/journal.
pmed.0050155
Using a Mendelian randomization 
approach, Eric Brunner and colleagues 
show that the associations between 
serum C-reactive protein and insulin 
resistance, glycemia, and diabetes are 
likely to be noncausal.
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Mendelian randomisation approach. 
This analysis showed that there was 
no significant evidence of association 
between CRP and either HOMA-
IR or HbA1c when genotypes were 
used as instruments. These findings 
suggest that the association observed 
in the analyses not incorporating 
genotype may have been due to 
residual confounding. However, the 
upper 95% confidence intervals for 
the “instrumental variable” analyses 
were generally similar to the upper 
95% confidence intervals for the 
analyses not incorporating genotype: 
thus, the genetic analyses could not, 
for the most part, rule out effects of 
the size suggested by the analyses not 
incorporating genotypes. 
Finally, Brunner and colleagues 
tested for an association between CRP
haplotypes and diabetes. Primary 
data were generated among 522 cases 
of diabetes and 6,534 controls from 
the Whitehall II study and a second 
prospective study, the Northwick 
Park Heart Study II. No association 
between any of the four most frequent 
haplotypes and incident diabetes 
was observed, although increases in 
diabetes risk between 30% and 60% for 
the different haplotypes could not be 
excluded. The publicly available data 
from the Wellcome Trust Case-Control 
Consortium (WTCCC) genome-wide 
association study in 1,923 cases of 
type II diabetes and 2,932 controls 
were also obtained. SNPs typed by 
the WTCCC that were good proxies 
for the three SNPs typed to generate 
Brunner and colleagues’ primary 
data were identified. There was no 
significant association (p > 0.05) with 
diabetes for any of the proxy SNPs 
in the WTCCC data; differences in 
diabetes risk of greater than about 10% 
were ruled out. The authors conclude 
that serum CRP levels do not lie in 
the causal pathway leading to insulin 
resistance, hyperglycemia, or diabetes, 
and speculate that more proximal 
mediators in the inflammatory cascade 
(such as interleukin-6, the principal 
regulator of CRP production) may be 
important.
Implications of the Study
This study provides significant 
additional evidence against major 
causal effects of CRP on quantitative 
phenotypes related to diabetes risk. 
By inclusion of the WTCCC data, the 
study provides the strongest argument 
yet against any material association 
of common SNPs in CRP that affect 
plasma CRP levels with type II diabetes. 
However, it also illustrates an 
important issue for the Mendelian 
randomisation approach—the 
difficulty of identifying common 
polymorphisms or haplotypes that 
have sufficiently large effects on 
intermediate traits that they can be 
used to draw definite conclusions. 
Although very large meta-analyses 
using a Mendelian randomisation 
framework are a potential solution 
[5], focusing on an alternative class of 
genetic variants for this type of analysis 
may also be a fruitful approach. “Low-
frequency, intermediate-penetrance” 
(LFIP) variants with substantial effects 
on quantitative phenotypes have 
now been identified in a number of 
genes. For example, premature stop 
codons (in populations of African 
origin) or hypomorphic alleles (in 
white populations) in the PCSK9 gene, 
which have around a 3% prevalence 
in each population, are associated 
with substantially lower levels of low-
density lipoprotein (LDL) cholesterol 
(28% and 15%, respectively) and lower 
levels of coronary heart disease (CHD) 
risk (88% and 47%, respectively) 
[6]. If we did not already know 
that raised LDL cholesterol causes 
CHD, the association between the 
PCSK9 variants, low LDL cholesterol, 
and low levels of CHD risk would 
have been compelling evidence 
in favour of a causal relationship 
between raised LDL cholesterol 
and CHD. Counterfactually, if the 
LDL cholesterol/CHD relationship 
observed in epidemiological 
studies had all along been due to 
confounding, the large effects of these 
PCSK9 variants on LDL cholesterol 
could well have been large enough to 
identify a discrepancy in a Mendelian 
randomisation analysis. 
Recent technological developments 
have transformed the speed and 
cost of genetic sequencing [7]. As a 
consequence, the deep resequencing 
of large numbers of individuals 
necessary to discover such LFIP 
variants in candidate genes can now 
be undertaken on a systematic basis. 
Although LFIP variants causing large 
effects on potentially causal risk factors 
of interest may not be present for 
all such factors, they should, when 
present, considerably facilitate future 
analyses of the type undertaken by 
Brunner and colleagues. 
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